GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Second Sight Medical Products Inc (NAS:EYES) » Definitions » Debt-to-EBITDA

Second Sight Medical Products (Second Sight Medical Products) Debt-to-EBITDA : -0.01 (As of Jun. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Second Sight Medical Products Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Second Sight Medical Products's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $0.15 Mil. Second Sight Medical Products's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $0.00 Mil. Second Sight Medical Products's annualized EBITDA for the quarter that ended in Jun. 2022 was $-12.46 Mil. Second Sight Medical Products's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Second Sight Medical Products's Debt-to-EBITDA or its related term are showing as below:

EYES's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.235
* Ranked among companies with meaningful Debt-to-EBITDA only.

Second Sight Medical Products Debt-to-EBITDA Historical Data

The historical data trend for Second Sight Medical Products's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Second Sight Medical Products Debt-to-EBITDA Chart

Second Sight Medical Products Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.09 -0.18 -0.03

Second Sight Medical Products Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.03 -0.05 -0.02 -0.01

Competitive Comparison of Second Sight Medical Products's Debt-to-EBITDA

For the Medical Devices subindustry, Second Sight Medical Products's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Second Sight Medical Products's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Second Sight Medical Products's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Second Sight Medical Products's Debt-to-EBITDA falls into.



Second Sight Medical Products Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Second Sight Medical Products's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.185 + 0.052) / -8.863
=-0.03

Second Sight Medical Products's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.151 + 0) / -12.456
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2022) EBITDA data.


Second Sight Medical Products  (NAS:EYES) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Second Sight Medical Products Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Second Sight Medical Products's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Second Sight Medical Products (Second Sight Medical Products) Business Description

Traded in Other Exchanges
N/A
Address
13170 Telfair Avenue, Sylmar, CA, USA, 91342
Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States.
Executives
Lisa Ellen Porter officer: Chief Medical Officer 778 CORDILLERAS AVE, SAN CARLOS CA 94070
Donald Dwyer officer: Chief Business Officer 54 CHERRY FARM LANE, WEST CHESTER PA 19382
Truc Le officer: COO 1905 WEST RED FOX ROAD, SANTA ANA CA 92704
Adam Mendelsohn director, officer: CEO C/O 5858 HORTON ST. SUITE 280, EMERYVILLE CA 94608
Brigid Makes officer: CFO 20245 SW 95TH AVENUE, TUALATIN OR 97062
Gregg Williams director, 10 percent owner PO BOX 200, WALLED LAKE MI 48390-0200
Wilford Dean Baker director 200 FLYNN ROAD, CAMARILLO CA 93012-8790
Larson Alexandra L.p. director 3797 BURNING TREE DRIVE, BLOOMFIELD HILLS MI 48302
Scott Dunbar officer: Acting CEO 13170 TELFAIR AVENUE, SYLMAR CA 91342
Edward Jonathon Sedo officer: Controller 4485 FORESTGLEN CT, MOORPARK CA 93021
Jonathan Will Mcguire director, officer: Chief Executive Officer 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Jessy Dana Dorn officer: VP-Clin & Scientific Affairs 12744 SAN FERNANDO RD. SUITE 400, SYLMAR CA 91342
Edward David Randolph officer: Vice President Manufacturing 12744 SAN FERNANDO ROAD, BLDG. 3, SYLMAR CA 91342
Matthew J Pfeffer director
Aaron Mendelsohn director 224 15TH STREET, SANTA MONICA CA 90402